NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

SCYNEXIS, Inc. (SCYX) Stock Analysis

SCYNEXIS, Inc. (SCYX) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SCYX

$3.79

−$0.01 (−0.39%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SCYX with… →

SCYX Key Statistics

As of Oct 21, 2026
Trading
Open
$3.89
Previous Close
$3.80
Day's Range
3.76–3.98
52-Week Range
3.53–9.12
Volume
69.91K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.06
Valuation
Market Cap
$37.66M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.96
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.89
Financials (FY)
Revenue (FY)
$20.60M+449.95%
Net Income (FY)
−$8.61M
Profit marginThe share of revenue left as profit after all costs and taxes.
−53.26%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
9.95M
1-Year Return
−39.34%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
283.10K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SCYX closed at $3.79, −39.34% over 1 year.

SCYNEXIS, Inc. (SCYX) has a market capitalization of $37.66M.

In fiscal 2025, SCYX reported revenue of $20.60M.

SCYX Stock Return by Calendar Year

SCYNEXIS, Inc. (SCYX) 10-year return: what $10,000 became

1 year
$10,000 $6,066
−39.34%
5 years
$10,000 $868
−91.32%
10 years
$10,000 $130
−98.70%

If you had invested $10,000 in SCYNEXIS, Inc. (SCYX) 10 years ago, at the close on October 21, 2016, it would have been worth $130 at the close on October 21, 2026: −98.70% in total, −35.25% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−25.14%
2025−47.77%
2024−45.74%
2023+42.95%
2022−74.43%
2021−20.26%
2020−15.93%
2019+88.80%
2018−79.22%
2017−27.27%
2016 (partial year)+52.63%

As of October 21, 2026.

SCYX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$20.60M−$8.61M−41.8%
2024$3.75M−$21.29M−568.3%
2023$140.14M$67.04M47.8%
2022$5.09M−$62.81M−1,233.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$20.60M—−$16.07M−$8.61M−41.8%
2024$3.75M$3.75M−$37.12M−$21.29M−568.3%
2023$140.14M$124.52M$72.67M$67.04M47.8%
2022$5.09M$4.46M−$85.76M−$62.81M−1,233.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SCYX Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricSCYXDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio1.962.107% below
Profit margin−53.26%−8.14%45.1 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

SCYNEXIS, Inc. (SCYX) is capitalised at $37.66M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 18 employees.

The most recent close on file for SCYX is $3.79, dated October 21, 2026. That is −$0.01 (−0.39%) against the previous close. Over the past 52 weeks the price has ranged from $3.53 to $9.12. The latest close sits 7.22% above that 52-week low.

Financial Health

In fiscal 2025, SCYNEXIS, Inc. reported revenue of $20.60M. Against the prior fiscal year total of $3.75M, that is a change of +449.95%. The same year closed with a net loss of $8.61M. The reported profit margin is −53.26%. That is 45.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −0.89.

Across the 4 fiscal years on file, revenue moves from $5.09M in 2022 to $20.60M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 1.96. On price-to-sales that is 6.67% below the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −39.34%. Across 10 years the annualized return works out at −35.25%. The reported beta is 1.06. Annualized volatility over the trailing 10 years is 80.1%.

Growth & Income

The record shows no dividend for SCYX.

So far in 2026 the total return is −25.14%. The strongest complete calendar year on file is 2019 at +88.80%; the weakest is 2018 at −79.22%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

SCYNEXIS, Inc. (SCYX) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
SCYNEXIS, Inc. SCYX $37.66M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. SCYNEXIS, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About SCYNEXIS, Inc.

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Visit website →